Home/Filings/4/0001562180-25-000189
4//SEC Filing

Danos Olivier 4

Accession 0001562180-25-000189

CIK 0001590877other

Filed

Jan 5, 7:00 PM ET

Accepted

Jan 6, 4:59 PM ET

Size

9.6 KB

Accession

0001562180-25-000189

Insider Transaction Report

Form 4
Period: 2025-01-02
Danos Olivier
Chief Scientific Officer
Transactions
  • Award

    Stock Options (Right to buy)

    2025-01-02+95,72195,721 total
    Exercise: $7.86Exp: 2035-01-02Common Stock (95,721 underlying)
  • Award

    Common Stock

    2025-01-02+59,347231,800 total
  • Tax Payment

    Common Stock

    2025-01-02$7.73/sh12,630$97,630172,453 total
Footnotes (3)
  • [F1]Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022, January 3, 2023 and January 2, 2024. The number of shares withheld was determined on January 2, 2025 based on the closing price of the issuer's common stock on December 31, 2024.
  • [F2]Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2026, January 1, 2027, January 1, 2028 and January 1, 2029 while the recipient provides continuous service to the Issuer.
  • [F3]25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer.

Issuer

REGENXBIO Inc.

CIK 0001590877

Entity typeother

Related Parties

1
  • filerCIK 0001701180

Filing Metadata

Form type
4
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 4:59 PM ET
Size
9.6 KB